INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 131 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $15,000 | -99.2% | 11,524 | -99.1% | 0.00% | -100.0% |
Q2 2017 | $1,958,000 | -53.6% | 1,246,959 | -4.6% | 0.04% | -53.1% |
Q1 2017 | $4,221,000 | +133.9% | 1,306,679 | -2.3% | 0.08% | +125.0% |
Q4 2016 | $1,805,000 | -15.0% | 1,336,821 | -1.8% | 0.04% | -16.3% |
Q3 2016 | $2,123,000 | +9.1% | 1,360,822 | -7.0% | 0.04% | +2.4% |
Q2 2016 | $1,946,000 | -74.9% | 1,463,042 | -0.5% | 0.04% | -74.7% |
Q1 2016 | $7,753,000 | -32.1% | 1,471,111 | +1.2% | 0.17% | -30.5% |
Q4 2015 | $11,414,000 | +0.4% | 1,453,981 | +8.0% | 0.24% | -5.2% |
Q3 2015 | $11,373,000 | – | 1,345,930 | – | 0.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |